PALVELLA THERAPEUTICS, INC.
PVLA evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $2.18B
- Lead Asset:
- qtorin rapamycin (Phase 3)
What it means
What to watch
Prepared research question
What matters most for PVLA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PVLA
Palvella Therapeutics (PVLA) is a rare-disease biopharmaceutical company developing topical therapies for serious skin diseases and vascular malformations using its proprietary QTORIN platform, with lead candidate QTORIN rapamycin under FDA review for microcystic lymphatic malformations.
Key risk: No approved products yet
BioSniper Score
Based on 4 of 6 signals
Market Cap
$2.18B
Cash Runway
—
Lead Asset
qtorin rapamycin (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 5 clinical trials for PALVELLA THERAPEUTICS, INC..
Palvella Therapeutics (PVLA) is a rare-disease biopharmaceutical company developing topical therapies for serious skin diseases and vascular malformations using its proprietary QTORIN platform, with lead candidate QTORIN rapamycin under FDA review for microcystic lymphatic malformations.
- Lead candidate QTORIN rapamycin (3.9% anhydrous topical gel) is under rolling NDA review for microcystic lymphatic malformations, with first module submitted June 2026 and completion expected H2 2026 [sec_mda · as of 2026-08-04].
- Positive topline results reported for Phase 3 SELVA study (microcystic LMs) and Phase 2 TOIVA study (cutaneous VMs) [sec_mda · as of 2026-08-04].
- Cash & equivalents $187.8M as of 2026-06-30; net income -$21.9M; shareholders' equity $216.9M [latest reported financials].
- Pipeline includes QTORIN pitavastatin for DSAP and preclinical programs for other rare skin diseases [sec_mda · as of 2026-08-04].
- Fast Track Designation received for cutaneous VMs program; Phase 3 pivotal study expected to commence Q4 2026 [sec_mda · as of 2026-08-04].
What works
- Strong cash position ($187.8M as of 2026-06-30) provides runway for planned commercial launch and pipeline expansion [latest reported financials].
- Positive Phase 3 (SELVA) and Phase 2 (TOIVA) results de-risk lead candidate QTORIN rapamycin for two indications [sec_mda · as of 2026-08-04].
- Fast Track Designation from FDA for cutaneous VMs program may accelerate regulatory review [sec_mda · as of 2026-08-04].
- Proprietary QTORIN platform enables topical delivery to deep skin layers, potentially reducing development timelines for rare skin disease therapies [sec_mda · as of 2026-08-04].
What to weigh
- Company has no approved products and has not yet generated any product revenue; net loss of $21.9M as of 2026-06-30 [latest reported financials].
- Regulatory approval and commercial launch are uncertain; NDA submission for QTORIN rapamycin is still in progress [sec_mda · as of 2026-08-04].
- Future capital needs depend on regulatory outcomes, commercialization costs, and R&D scope; additional financing may be required [sec_mda · as of 2026-08-04].
- Competition from existing or emerging therapies for vascular malformations and rare skin diseases could impact market adoption [sec_mda · as of 2026-08-04].
From the filings
Quoted directly from source documents.
Lead candidate QTORIN rapamycin is under rolling NDA review for microcystic LMs.
“In June 2026, we submitted the first module of our rolling NDA. We remain on track to submit the remaining modules and complete the NDA submission in the second half of 2026.”
SEC MD&A · August 4, 2026
Positive topline results for Phase 3 SELVA and Phase 2 TOIVA studies.
“We announced positive topline results for two clinical trials: (i) SELVA, a Phase 3, single-arm, baseline-controlled study evaluating the safety and efficacy of QTORIN rapamycin for the treatment of microcystic LMs in patients 3 years and older and (ii) TOIVA, a Phase 2, single-arm, open-label, baseline-controlled study evaluating the safety and efficacy of QTORIN rapamycin for the treatment of cutaneous VMs in patients 6 years and older.”
SEC MD&A · August 4, 2026
Fast Track Designation for cutaneous VMs program.
“We have received Fast Track Designation from the FDA for our cutaneous VMs program.”
SEC MD&A · August 4, 2026
Catalyst timeline
- 2024-07-31 · Phase 3 start for SELVA (microcystic LMs) — Multicenter baseline-controlled study evaluating QTORIN rapamycin for microcystic LMs.
- 2024-12-20 · Phase 2 start for TOIVA (cutaneous VMs) — Baseline-controlled study evaluating QTORIN rapamycin for cutaneous venous malformations.
- 2026-04-01 · Phase 2 start for LOTU (angiokeratomas) — Baseline-controlled study evaluating QTORIN rapamycin for angiokeratomas.
Risks & what to watch (4)›
Key risks
- No approved products yet — Palvella has no FDA-approved products and no product revenue; net loss of $21.9M as of 2026-06-30 [latest reported financials].
- Regulatory approval uncertainty — NDA for QTORIN rapamycin is incomplete; FDA review outcome and timeline are unknown [sec_mda · as of 2026-08-04].
- Future capital needs — Additional funding may be required depending on regulatory outcomes, commercialization costs, and R&D scope [sec_mda · as of 2026-08-04].
- Competitive landscape — Existing or emerging therapies for rare skin diseases and vascular malformations could limit market share [sec_mda · as of 2026-08-04].
What to watch
- Completion of rolling NDA submission for QTORIN rapamycin (microcystic LMs) in H2 2026 [sec_mda · as of 2026-08-04].
- FDA decision and potential commercial launch of QTORIN rapamycin in H1 2027 [sec_mda · as of 2026-08-04].
- End-of-Phase 2 meeting and start of Phase 3 pivotal study for cutaneous VMs in Q4 2026 [sec_mda · as of 2026-08-04].
- Progress of QTORIN pitavastatin for DSAP and other preclinical pipeline programs [sec_mda · as of 2026-08-04].
Sources: Catalysts · News · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run PALVELLA THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PALVELLA THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.17 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
0 buys · 15 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
181
Total value held
$1.60B
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 1,153,496 | $143.8M |
| first light asset management, llc | 980,758 | $122.3M |
| bvf inc/il | 960,989 | $119.8M |
| frazier life sciences management, l.p. | 882,400 | $110.0M |
| blackrock, inc. | 686,853 | $85.6M |
| jennison associates llc | 640,611 | $79.9M |
| vanguard capital management llc | 477,294 | $59.5M |
| state street corp | 458,999 | $57.2M |
| federated hermes, inc. | 433,015 | $54.0M |
| frontier capital management co llc | 374,035 | $46.6M |
Showing top 10 of 181 institutional holders of PALVELLA THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 17.2%
- Days to cover
- 9.1
- Shares short
- 2,170,623
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PVLA short interestGovernance
Frequently asked questions
What is the AI investment thesis for PALVELLA THERAPEUTICS, INC.?
Palvella Therapeutics (PVLA) is a rare-disease biopharmaceutical company developing topical therapies for serious skin diseases and vascular malformations using its proprietary QTORIN platform, with lead candidate QTORIN rapamycin under FDA review for microcystic lymphatic malformations.
What is PALVELLA THERAPEUTICS, INC.'s lead drug candidate?
PALVELLA THERAPEUTICS, INC.'s most advanced tracked candidate is qtorin rapamycin (Phase 3) for Cutaneous Venous Malformations; Microcystic Lymphatic Malformation.
Who is the CEO of PALVELLA THERAPEUTICS, INC.?
Mr. Wesley H. Kaupinen is the chief executive officer of PALVELLA THERAPEUTICS, INC. (PVLA).
Where is PALVELLA THERAPEUTICS, INC. headquartered?
PALVELLA THERAPEUTICS, INC. (PVLA) is headquartered in Wayne, PA, United States.
What therapeutic areas does PALVELLA THERAPEUTICS, INC. focus on?
PALVELLA THERAPEUTICS, INC. develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.